WO2011099832A3 - Novel benzimidazole compound, preparation method thereof and pharmaceutical composition comprising the same - Google Patents

Novel benzimidazole compound, preparation method thereof and pharmaceutical composition comprising the same Download PDF

Info

Publication number
WO2011099832A3
WO2011099832A3 PCT/KR2011/000976 KR2011000976W WO2011099832A3 WO 2011099832 A3 WO2011099832 A3 WO 2011099832A3 KR 2011000976 W KR2011000976 W KR 2011000976W WO 2011099832 A3 WO2011099832 A3 WO 2011099832A3
Authority
WO
WIPO (PCT)
Prior art keywords
pharmaceutical composition
preparation
benzimidazole compound
same
novel benzimidazole
Prior art date
Application number
PCT/KR2011/000976
Other languages
French (fr)
Other versions
WO2011099832A2 (en
Inventor
Eun Bok Choi
Hyeon Kyu Lee
Eun Sil Lee
Chwang Siek Pak
Dong Kyu Shin
Mi Yeon Bang
Seonggu Ro
Joong Myong Cho
Original Assignee
Crystalgenomics, Inc.
Korea Research Institute Of Chemical Technology
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Crystalgenomics, Inc., Korea Research Institute Of Chemical Technology filed Critical Crystalgenomics, Inc.
Publication of WO2011099832A2 publication Critical patent/WO2011099832A2/en
Publication of WO2011099832A3 publication Critical patent/WO2011099832A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

The present invention relates to a novel benzimidazole compound, a pharmaceutical composition for preventing or treating an inflammatory disease comprising said compound, a use of a novel benzimidazole compound for the manufacture of a medicament for preventing or treating an inflammatory disease, and a method of preventing or treating an inflammatory disease in a mammal comprising administering to the mammal said compound.
PCT/KR2011/000976 2010-02-12 2011-02-14 Novel benzimidazole compound, preparation method thereof and pharmaceutical composition comprising the same WO2011099832A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR10-2010-0013590 2010-02-12
KR20100013590 2010-02-12

Publications (2)

Publication Number Publication Date
WO2011099832A2 WO2011099832A2 (en) 2011-08-18
WO2011099832A3 true WO2011099832A3 (en) 2012-01-12

Family

ID=44368346

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2011/000976 WO2011099832A2 (en) 2010-02-12 2011-02-14 Novel benzimidazole compound, preparation method thereof and pharmaceutical composition comprising the same

Country Status (1)

Country Link
WO (1) WO2011099832A2 (en)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2700542T3 (en) 2010-06-24 2019-02-18 Gilead Sciences Inc Pharmaceutical composition comprising a pyrazolo [1,5-A] pyrimidine derivative as an antiviral agent
RU2013109143A (en) * 2010-08-05 2014-09-10 Амджен Инк. Benzimidazole- and azabenzimidazole-containing compounds that inhibit the kinase of anaplastic lymphoma
US10292390B2 (en) 2011-11-04 2019-05-21 Wisconsin Alumni Research Foundation Inhibition and dispersion of bacterial biofilms with 2-aminobenzimidazole derivatives
JP6122868B2 (en) 2011-12-22 2017-04-26 ギリアード サイエンシーズ， インコーポレイテッド Pyrazolo [1,5-A] pyrimidine as an antiviral agent
IN2014DN09173A (en) 2012-04-17 2015-07-10 Gilead Sciences Inc
JO3300B1 (en) 2012-06-06 2018-09-16 Novartis Ag Compounds and compositions for modulating egfr activity
WO2014147021A2 (en) 2013-03-20 2014-09-25 Bayer Pharma Aktiengesellschaft Novel compounds
PT3119762T (en) 2014-03-20 2021-08-31 Capella Therapeutics Inc Benzimidazole derivatives as erbb tyrosine kinase inhibitors for the treatment of cancer
CA2943231C (en) 2014-03-20 2023-10-24 Capella Therapeutics, Inc. Benzimidazole derivatives as erbb tyrosine kinase inhibitors for the treatment of cancer
WO2015166398A1 (en) * 2014-04-30 2015-11-05 Aurigene Discovery Technologies Limited 3h-imidazo[4,5-b]pyridine derivatives as dihydroorotate dehydrogenase inhibitors
CN104326937B (en) 2014-09-03 2016-08-24 天津市肿瘤研究所 Antitumoral compounds and medical usage thereof
CN104387350B (en) * 2014-10-31 2016-03-16 中科院广州化学有限公司 A kind of preparation method containing cumarone structural compounds
US9586949B2 (en) 2015-02-09 2017-03-07 Incyte Corporation Aza-heteroaryl compounds as PI3K-gamma inhibitors
WO2016161572A1 (en) * 2015-04-08 2016-10-13 Merck Sharp & Dohme Corp. TrkA KINASE INHIBITORS, COMPOSITIONS AND METHODS THEREOF
GB201506660D0 (en) 2015-04-20 2015-06-03 Cellcentric Ltd Pharmaceutical compounds
GB201506658D0 (en) 2015-04-20 2015-06-03 Cellcentric Ltd Pharmaceutical compounds
WO2017053537A1 (en) 2015-09-23 2017-03-30 Capella Therapeutics, Inc. Benzimidazoles for use in the treatment of cancer and inflammatory diseases
AR106595A1 (en) 2015-11-06 2018-01-31 Incyte Corp HETEROCYCLIC COMPOUNDS AS PI3K-g INHIBITORS
ES2833955T3 (en) 2016-01-05 2021-06-16 Incyte Corp Pyridines substituted with pyrazole / imidazole as PI3K-Gamma inhibitors
WO2017223414A1 (en) 2016-06-24 2017-12-28 Incyte Corporation HETEROCYCLIC COMPOUNDS AS PI3K-γ INHIBITORS
CN106905303A (en) * 2017-03-16 2017-06-30 北京师范大学 The compound and its label and their preparation method and application of one class targeting FAK
EP4006034A1 (en) 2017-10-18 2022-06-01 Incyte Corporation Condensed imidazole derivatives substituted by tertiary hydroxy groups as pi3k-gamma inhibitors
JP7312171B2 (en) 2017-11-24 2023-07-20 ヤンセン ファーマシューティカ エヌ．ベー． pyrazolopyridinone compound
MA53561A (en) 2018-09-05 2022-05-11 Incyte Corp CRYSTALLINE FORMS OF A PHOSPHOINOSITIDE 3-KINASE (PI3K) INHIBITOR
PE20221003A1 (en) * 2019-06-12 2022-06-15 Tmem16A Ltd COMPOUNDS TO TREAT RESPIRATORY DISEASE
CA3166630A1 (en) 2020-01-03 2021-07-08 Berg Llc Polycyclic amides as ube2k modulators for treating cancer
WO2022123314A1 (en) * 2020-12-11 2022-06-16 Tmem16A Limited Benzimidazole derivatives for treating respiratory disease
CN115399179A (en) * 2021-05-27 2022-11-29 中国科学院化学研究所 Application of polysaccharide-based cationic polymer in prevention and treatment of soil-borne diseases of agriculture and forestry
WO2023044364A1 (en) 2021-09-15 2023-03-23 Enko Chem, Inc. Protoporphyrinogen oxidase inhibitors
WO2024029819A1 (en) * 2022-08-01 2024-02-08 경희대학교 산학협력단 Pharmaceutical composition containing benzimidazole derivative or pharmaceutically acceptable salt thereof, and method for preparing same

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008048991A2 (en) * 2006-10-18 2008-04-24 Novartis Ag Organic compounds
WO2008084218A1 (en) * 2007-01-12 2008-07-17 Boehringer Ingelheim International Gmbh Benzazole derivatives for the treatment of inflammations
WO2009019504A1 (en) * 2007-08-03 2009-02-12 Summit Corporation Plc Drug combinations for the treatment of duchenne muscular dystrophy
WO2010034796A1 (en) * 2008-09-25 2010-04-01 Boehringer Ingelheim International Gmbh 1h-benz imidazole-5-carboxamides as anti-inflammatory agents

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008048991A2 (en) * 2006-10-18 2008-04-24 Novartis Ag Organic compounds
WO2008084218A1 (en) * 2007-01-12 2008-07-17 Boehringer Ingelheim International Gmbh Benzazole derivatives for the treatment of inflammations
WO2009019504A1 (en) * 2007-08-03 2009-02-12 Summit Corporation Plc Drug combinations for the treatment of duchenne muscular dystrophy
WO2010034796A1 (en) * 2008-09-25 2010-04-01 Boehringer Ingelheim International Gmbh 1h-benz imidazole-5-carboxamides as anti-inflammatory agents
WO2010034799A1 (en) * 2008-09-25 2010-04-01 Boehringer Ingelheim International Gmbh 3h-imidaz0 [4, 5-b] pyridine- 6 -carboxamides as anti -inflammatory agents

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
MADER, M. ET AL.: "Imidazolyl benzimidazoles and imidazo[4,5-b]pyridines as p otent p38a MAP kinase inhibitors with excellent in vivo antiinflammatory pro perties", BIOORG. MED. CHEM. LETT., vol. 18, 2008, pages 179 - 183 *
SHAH, U. A. ET AL.: "3D-QSAR and pharmacophore identification of novel imidaz olyl benzimidazoles and imidazo[4,5-b]pyridines as potent p38a mitogen activ ated protein kinase inhibitors", INTERNATIONAL J. CHEMTECH RES., vol. 2, no. 1, 2010, pages 194 - 204 *

Also Published As

Publication number Publication date
WO2011099832A2 (en) 2011-08-18

Similar Documents

Publication Publication Date Title
WO2011099832A3 (en) Novel benzimidazole compound, preparation method thereof and pharmaceutical composition comprising the same
IL223783B (en) Substituted 1-indole compound for use in the treatment of a disease or condition, a pharmaceutical composition comprising the compound and use of the compound for the preparation of a medicament
WO2011127333A3 (en) Compounds for treating disease, for administering, and for pharmaceutical compositions
WO2012104655A3 (en) Compostions and methods for treating chronic inflammation and inflammatory diseases
WO2012024620A3 (en) Autotaxin inhibitors and uses thereof
AU2016219643A1 (en) Pharmaceutical combination for the treatment of pain
WO2012088266A3 (en) Substituted imidazopyridazines and benzimidazoles as inhibitors of fgfr3
WO2013052699A3 (en) Novel quinoxaline inhibitors of pi3k
IL224544B (en) Compound useful for the treatment of nonsense-mutation-mediated diseases and pharmaceutical composition comprising said compound
IL219610A (en) Compositions comprising derivatives of 3-hydroxy-2-oxo-1,2-dihydropyridine for use in the treatment or in the manufacture of a medicament for treating an inflammatory epithelial disease
WO2008148074A3 (en) Inhibitors of mtor and methods of treatment using same
WO2010003992A8 (en) Combination of a c-met antagonist and an aminoheteroaryl compound for the treatment of cancer
WO2011086093A3 (en) Pharmaceutical compositions for oral administration of insulin peptides
MY149028A (en) Nalmefene hydrochloride dihydrate
MX347734B (en) S100a4 antibodies and therapeutic uses thereof.
IT1404931B1 (en) OPHTHALMIC COMPOSITIONS FOR THE ADMINISTRATION OF LIPO-SOLUBLE ACTIVE PRINCIPLES.
CL2014000849A1 (en) Compounds derived from substituted benzylindazoles, bub1 kinase inhibitors; manufacturing procedure; pharmaceutical composition; pharmaceutical combination; and its use in the treatment of hyperproliferative diseases.
MX2013003635A (en) N-heteroaryl compounds.
GB201213267D0 (en) Azetidine derivatives useful for the treatment of metabolic and inflammatory diseases
WO2012162439A3 (en) Compositions comprising fusidic acid and packages therefor
WO2012071369A3 (en) A non-retinoid rbp4 antagonist for treatment of age-related macular degeneration and stargardt disease
UA111599C2 (en) COMPOSITION OF CASPOFUNGIN
WO2014107730A3 (en) Use of fatty acid niacin conjugates for treating diseases
IL213671A (en) Pharmaceutical compositions comprising aleglitazar, process for their manufacture and use thereof in the preparation of medicaments
IL210975A (en) Enfumafungin derivatives, pharmaceutical compositions comprising them and use thereof for the preparation of medicaments for treating fungal infections

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 11742524

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

32PN Ep: public notification in the ep bulletin as address of the adressee cannot be established

Free format text: NOTING OF LOSS OF RIGHTS PURSUANT TO RULE 112(1) EPC (EPO FORM 1205A DATED 27-11-2012.)

122 Ep: pct application non-entry in european phase

Ref document number: 11742524

Country of ref document: EP

Kind code of ref document: A2